Rejected Proposals, Earnings Results, and Financial Outlook - Analyst Notes on Allergan, Isis, Depomed, Lannett and Orexigen

NEW YORK, May 15, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Allergan Inc. (NYSE: AGN), Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), Depomed Inc. (NASDAQ: DEPO), Lannett Company, Inc. (NYSE: LCI) and Orexigen Therapeutics, Inc. (NYSE: OREX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2490-100free.

--
Allergan Inc. Analyst Notes
On May 12, 2014, Allergan, Inc. (Allergan) announced its Board of Directors' unanimous decision to reject the unsolicited proposal (Proposal) announced by Valeant Pharmaceuticals International, Inc. (Valeant) on April 22, 2014. According to the Company, the Allergan Board concluded that the Proposal substantially undervalues Allergan, creates significant risks and uncertainties for the stockholders of Allergan, and is not in the best interests of the Company and its stockholders. Further, the Company also expects to increase EPS by 20% to 25% and continue to generate double digit revenue growth in 2015. The full analyst notes on Allergan are available to download free of charge at:

http://www.analystsreview.com/2490-AGN-15May2014.pdf

--
Isis Pharmaceuticals, Inc. Analyst Notes
On May 6, 2014, Isis Pharmaceuticals, Inc. (Isis) reported its Q1 2014 financial results with revenue of $28.2 million compared to $43.4 million in Q1 2013. Isis stated that its revenue fluctuates based on the nature and timing of payments under agreements with its partners, including license fees, milestone-related payments and other payments. Q1 2014 net loss totaled $31.3 million compared to $1.7 million in Q1 2013. Basic and diluted net loss per share was $0.27 for Q1 2014 compared to $0.02 in Q1 2013. According to Isis, increase in net loss was primarily due to variations in the timing of revenue from milestone payments and an increase in operating expenses associated with the Company's maturing pipeline of drugs. The full analyst notes on Isis are available to download free of charge at:

http://www.analystsreview.com/2490-ISIS-15May2014.pdf

--
Depomed Inc. Analyst Notes
On May 8, 2014, Depomed, Inc. (Depomed) reported its unaudited Q1 2014 financial results with revenue of $76.5 million compared to $26.2 million in Q1 2013. GAAP net income totaled $17.9 million, or $0.30 per diluted share compared to a net loss of $5.5 million, or $0.10 per diluted share in Q1 2013. Depomed reiterated its financial outlook for full-year 2014 with total revenues of approximately $200 million to $215 million and GAAP EPS of approximately $0.21 to $0.36 per share. The full analyst notes on Depomed are available to download free of charge at:

http://www.analystsreview.com/2490-DEPO-15May2014.pdf

--
Lannett Company, Inc. Analyst Notes
On May 7, 2014, Lannett Company, Inc. (Lannett) reported its Q3 FY 2014 financial results (period ended March 31, 2014). The Company reported Q3 FY 2014 net sales of $80 million compared to $39.0 million in Q3 FY 2013. Q3 FY 2014 net income attributable to Lannett totaled $23 million, or $0.63 per diluted share compared to $3.9 million, or $0.14 per diluted share in Q3 FY 2013. Arthur Bedrosian, President and CEO of Lannett stated, "Our excellent financial performance was largely driven by price increases across multiple product categories and strong sales of existing products." The Company expects FY 2014 net sales to be in the range of $261 million to $267 million, below the previous guidance of $275 million to $285 million. The full analyst notes on Lannett are available to download free of charge at:

http://www.analystsreview.com/2490-LCI-15May2014.pdf

--
Orexigen Therapeutics, Inc. Analyst Notes
On May 8, 2014, Orexigen Therapeutics, Inc. (Orexigen) reported its unaudited Q1 2014 financial results with net loss of $24.9 million, or $0.23 per diluted share compared to a net loss of $19.4 million, or $0.21 per diluted share in Q1 2013. Revenues totaled $857,000 which remained flat as compared to Q1 2013. As of March 31, 2014, Orexigen had $37.6 million in cash and cash equivalents and an additional $117.5 million in marketable securities. The full analyst notes on Orexigen are available to download free of charge at:

http://www.analystsreview.com/2490-OREX-15May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED